

John C Byrd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2312971/publications.pdf>

Version: 2024-02-01

373
papers

22,028
citations

19655

61
h-index

9588

142
g-index

375
all docs

375
docs citations

375
times ranked

17515
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic utility of bronchoscopy in newly diagnosed acute leukemia patients. Hematological Oncology, 2022, 40, 116-119.	1.7	1
2	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia, 2022, 36, 1171-1175.	7.2	72
3	DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo. Small, 2022, 18, .	10.0	40
4	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. Journal of Clinical Oncology, 2022, 40, 3709-3718.	1.6	9
5	Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. Journal of Hematology and Oncology, 2022, 15, .	17.0	7
6	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2021, 62, 716-721.	1.3	3
7	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2021, 14, 17.	17.0	31
8	Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clinical Cancer Research, 2021, 27, 2352-2366.	7.0	15
9	Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. Journal of Hematology and Oncology, 2021, 14, 36.	17.0	9
10	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Research, 2021, 31, 747-761.	5.5	20
11	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 2021, 35, 3287-3290.	7.2	0
12	Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms. American Journal of Hematology, 2021, 96, E223-E225.	4.1	2
13	Preclinical Characterization of TP53, a Novel Multikinase Inhibitor, in TP53 Mutant Acute Myeloid Leukemia. FASEB Journal, 2021, 35, .	0.5	1
14	Whole-genome sequencing for myeloid disease: one assay to stratify them all?. Nature Reviews Clinical Oncology, 2021, 18, 543-544.	27.6	4
15	Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.. Journal of Clinical Oncology, 2021, 39, 7509-7509.	1.6	19
16	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia, 2021, 35, 3406-3420.	7.2	3
17	Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation. Journal of Hematology and Oncology, 2021, 14, 101.	17.0	8
18	A precision medicine classification for treatment of acute myeloid leukemia in older patients. Journal of Hematology and Oncology, 2021, 14, 96.	17.0	5

#	ARTICLE	IF	CITATIONS
19	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	1.4	47
20	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3441-3452.	1.6	266
21	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	7.2	12
22	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021, 5, 2775-2787.	5.2	15
23	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
24	Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model. <i>Experimental Hematology and Oncology</i> , 2021, 10, 50.	5.0	2
25	Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. <i>Cancer Research Communications</i> , 2021, 1, 79-89.	1.7	6
26	Rare t(X;14)(q28;q32) translocation reveals link between MTC1 and chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 6338.	12.8	3
27	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 720704.	2.8	27
28	Simultaneous Disruption of XPO1 and A20 in Murine B Cells Influences Both B and T Cell Repertoire. <i>Blood</i> , 2021, 138, 1542-1542.	1.4	0
29	Performance of Standard Prognostic Models in Older Adults Receiving Ibrutinib for Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): A Post Hoc Analysis of Alliance A041202 Phase 3 Trial. <i>Blood</i> , 2021, 138, 2642-2642.	1.4	5
30	Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib. <i>Blood</i> , 2021, 138, 3731-3731.	1.4	3
31	PRMT5 Inhibition Modulates E2F1 and P53 to Restore Cell Cycle Regulation and Drive DNA Damage Response in Ibrutinib-Resistant Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 787-787.	1.4	0
32	Transducin β -like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2927-2939.	3.5	5
33	Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. <i>Investigational New Drugs</i> , 2020, 38, 340-349.	2.6	28
34	Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020, 61, 387-396.	1.3	29
35	T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 7-15.	2.0	37
36	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. <i>Leukemia</i> , 2020, 34, 358-368.	7.2	8

#	ARTICLE	IF	CITATIONS
37	Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 214-231.	9.4	27
38	Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa070.	3.2	8
39	Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 139.	17.0	39
40	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.8	40
41	Pharmacokinetics and Tolerability of the Novel Non-immunosuppressive Fingolimod Derivative, OSU-2S, in Dogs and Comparisons with Data in Mice and Rats. <i>AAPS Journal</i> , 2020, 22, 92.	4.4	3
42	A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2020, 95, 1457-1465.	4.1	2
43	Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2276.	2.4	6
44	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637.	1.6	71
45	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	30.7	104
46	Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 6187-6195.	7.0	3
47	Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia. <i>Cytotherapy</i> , 2020, 22, 369-376.	0.7	13
48	Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged ≤60 years. <i>Leukemia</i> , 2020, 34, 3215-3227.	7.2	66
49	Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 1574.	3.7	10
50	Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL. <i>Genome Medicine</i> , 2020, 12, 29.	8.2	15
51	CLEAR: coverage-based limiting-cell experiment analysis for RNA-seq. <i>Journal of Translational Medicine</i> , 2020, 18, 63.	4.4	11
52	Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 8.	17.0	16
53	Management of <sc>CLL</sc> patients early in the <sc>COVID</sc>â€19 pandemic: An international survey of <sc>CLL</sc> experts. <i>American Journal of Hematology</i> , 2020, 95, E199-E203.	4.1	20
54	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	1.4	130

#	ARTICLE	IF	CITATIONS
55	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1278-1291.	13.7	393
56	Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. <i>Methods in Enzymology</i> , 2020, 645, 79-107.	1.0	6
57	TP-0903 is active in models of drug-resistant acute myeloid leukemia. <i>JCI Insight</i> , 2020, 5, .	5.0	14
58	Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib. <i>Blood</i> , 2020, 136, 32-33.	1.4	6
59	Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance). <i>Blood</i> , 2020, 136, 20-21.	1.4	2
60	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3.	1.4	1
61	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10.	1.4	12
62	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2020, 136, 5-7.	1.4	4
63	Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial. <i>Blood</i> , 2020, 136, 27-30.	1.4	3
64	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 185-217.	4.9	40
65	Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
66	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 22-23.	1.4	1
67	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
68	Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy. <i>Blood</i> , 2020, 136, 29-30.	1.4	1
69	Use of <sc>PD</sc> (<sc>PDCD</sc>1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre. <i>British Journal of Haematology</i> , 2019, 185, 363-366.	2.5	22
70	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. <i>Journal of Geriatric Oncology</i> , 2019, 10, 479-485.	1.0	64
71	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3461-3469.	1.3	16
72	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 715-722.e6.	0.4	35

#	ARTICLE	IF	CITATIONS
73	Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. <i>British Journal of Haematology</i> , 2019, 187, 399-402.	2.5	10
74	Î¼-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6260-6273.	7.0	17
75	A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 4955-4965.	7.0	30
76	Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. <i>Leukemia</i> , 2019, 33, 2527-2530.	7.2	65
77	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	1.4	178
78	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2498-2507.	1.3	21
79	Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL. <i>Cancer Discovery</i> , 2019, 9, 320-322.	9.4	7
80	Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. <i>Journal of Immunology</i> , 2019, 202, 2806-2816.	0.8	22
81	Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). <i>Leukemia and Lymphoma</i> , 2019, 60, 2580-2583.	1.3	0
82	Low-cost, simple, and scalable self-assembly of DNA origami nanostructures. <i>Nano Research</i> , 2019, 12, 1207-1215.	10.4	24
83	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , 2019, 33, 1620-1634.	7.2	55
84	HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. <i>Leukemia and Lymphoma</i> , 2019, 60, 2308-2311.	1.3	5
85	Targeting PI3KÎ function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019, 19, 1820-1830.	4.7	9
86	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019, 3, 1553-1562.	5.2	145
87	Hypertension and incident cardiovascular events following ibrutinib initiation. <i>Blood</i> , 2019, 134, 1919-1928.	1.4	155
88	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019, 185, 961-966.	2.5	12
89	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 1000-1005.	1.3	17
90	Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy. <i>Blood</i> , 2019, 134, 3045-3045.	1.4	1

#	ARTICLE	IF	CITATIONS
91	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. Blood, 2019, 134, 3049-3049.	1.4	2
92	Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.. Journal of Clinical Oncology, 2019, 37, 7510-7510.	1.6	1
93	Second cancer incidence in CLL patients receiving BTK inhibitors.. Journal of Clinical Oncology, 2019, 37, 7511-7511.	1.6	2
94	Restoring Functional Deficits in Older Adults with Hematologic Malignancy. Blood, 2019, 134, 4776-4776.	1.4	0
95	Role of Mutant p53 in the Progression of Chronic Lymphocytic Leukemia. Blood, 2019, 134, 2526-2526.	1.4	1
96	Identification of Novel Synthetic Lethal Partners of NAMPT Inhibitor By CRISPR-Cas9 Screens in Acute Myeloid Leukemia. Blood, 2019, 134, 2072-2072.	1.4	0
97	The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia. Blood, 2019, 134, 2077-2077.	1.4	1
98	Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia. JAMA Oncology, 2018, 4, 712.	7.1	20
99	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia, 2018, 32, 1338-1348.	7.2	80
100	BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discovery, 2018, 8, 458-477.	9.4	101
101	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood, 2018, 131, 1910-1919.	1.4	339
102	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 2018, 131, 2745-2760.	1.4	1,069
103	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica, 2018, 103, 982-987.	3.5	16
104	Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leukemia and Lymphoma, 2018, 59, 1461-1465.	1.3	2
105	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2018, 19, 65-75.	10.7	314
106	A single-institution retrospective cohort study of first-line Râ€œEPOCH</scp> chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. British Journal of Haematology, 2018, 180, 259-266.	2.5	53
107	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	27.0	706
108	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Advances, 2018, 2, 1645-1650.	5.2	85

#	ARTICLE	IF	CITATIONS
109	Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. <i>Biochemistry</i> , 2018, 57, 3564-3575.	2.5	261
110	Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. <i>Blood</i> , 2018, 132, 1039-1049.	1.4	51
111	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. <i>Cancer Discovery</i> , 2018, 8, 1300-1315.	9.4	115
112	Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. <i>International Immunology</i> , 2018, 30, 375-383.	4.0	21
113	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. <i>Leukemia</i> , 2018, 32, 2536-2545.	7.2	33
114	PLK1: a promising and previously unexplored target in double-hit lymphoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5206-5208.	8.2	9
115	PI3K p110 α inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. <i>Journal of Clinical Investigation</i> , 2018, 129, 122-136.	8.2	42
116	Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 693-693.	1.4	15
117	Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7048-7048.	1.6	7
118	Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7512-7512.	1.6	2
119	Depth of response and progression free survival in CLL patients on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7514-7514.	1.6	2
120	Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7528-7528.	1.6	1
121	A U.S.-based survey: The experiences of 1147 chronic lymphocytic leukemia (CLL) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7532-7532.	1.6	1
122	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7521-7521.	1.6	0
123	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	1.4	1
124	Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment. <i>Blood</i> , 2018, 132, 3148-3148.	1.4	0
125	Sweet-Like Eruption Associated With Obinutuzumab Therapy for Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2017, 153, 108.	4.1	2
126	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318.	1.3	43

#	ARTICLE	IF	CITATIONS
127	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British Journal of Haematology, 2017, 178, 286-291.	2.5	55
128	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2831-2841.	7.0	123
129	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 293-311.	4.9	55
130	The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. Cancer Medicine, 2017, 6, 778-787.	2.8	15
131	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2017, 176, 618-628.	2.5	36
132	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	3.5	200
133	Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia. British Journal of Haematology, 2017, 176, 86-91.	2.5	29
134	Mutational Landscape and Gene Expression Patterns in Adult Acute Myeloid Leukemias with Monosomy 7 as a Sole Abnormality. Cancer Research, 2017, 77, 207-218.	0.9	23
135	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Advances, 2017, 1, 1739-1748.	5.2	123
136	Ibrutinib treatment improves T cell number and function in CLL patients. Journal of Clinical Investigation, 2017, 127, 3052-3064.	8.2	280
137	Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. Blood, 2017, 130, 830-830.	1.4	27
138	CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. Journal of Clinical Oncology, 2017, 35, 7509-7509.	1.6	30
139	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€”A two-cohort phase II study.. Journal of Clinical Oncology, 2017, 35, TPS7567-TPS7567.	1.6	0
140	Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE, 2016, 11, e0159607.	2.5	49
141	Reprogramming Nurse-like Cells with Interferon γ to Interrupt Chronic Lymphocytic Leukemia Cell Survival. Journal of Biological Chemistry, 2016, 291, 14356-14362.	3.4	21
142	Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug Resistance Mechanisms in a Leukemia Model. Small, 2016, 12, 308-320.	10.0	191
143	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1067-1079.	4.9	107
144	Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance). Haematologica, 2016, 101, 1516-1523.	3.5	13

#	ARTICLE	IF	CITATIONS
145	Targeting BTK through microRNA in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 3101-3112.	1.4	30
146	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	59
147	DNA Origami: Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model (Small 3/2016). <i>Small</i> , 2016, 12, 307-307.	10.0	7
148	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 79-86.	1.4	72
149	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016, 127, 1117-1127.	1.4	381
150	A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2212-2215.	1.3	13
151	A New Role for Lyn in the CLL Microenvironment. <i>Cancer Cell</i> , 2016, 30, 511-512.	16.8	5
152	Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 226-236.	2.5	49
153	Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2016, 95, 1989-1997.	1.8	19
154	Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. <i>Onc Immunology</i> , 2016, 5, e1226720.	4.6	105
155	A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells. <i>Onc Immunology</i> , 2016, 5, e1151592.	4.6	17
156	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. <i>Annals of Hematology</i> , 2016, 95, 1137-1143.	1.8	31
157	Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. <i>Cancer Immunology Research</i> , 2016, 4, 698-707.	3.4	15
158	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	2.4	68
159	DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2016, 48, 253-264.	21.4	254
160	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	27.0	785
161	MuCor: mutation aggregation and correlation. <i>Bioinformatics</i> , 2016, 32, 1557-1558.	4.1	17
162	Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. <i>Cancer Research</i> , 2016, 76, 2125-2136.	0.9	150

#	ARTICLE	IF	CITATIONS
163	NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines. <i>Cancer Immunology Research</i> , 2016, 4, 323-336.	3.4	5
164	Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 265-273.	2.2	18
165	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 830-841.	4.1	35
166	Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells. <i>Onc Immunology</i> , 2016, 5, e1057385.	4.6	31
167	Venetoclax Adds a New Arrow Targeting Relapsed CLL to the Quiver. <i>Cancer Cell</i> , 2016, 29, 3-4.	16.8	3
168	Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia. <i>Blood</i> , 2016, 128, 1259-1259.	1.4	5
169	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. <i>Blood</i> , 2016, 128, 2040-2040.	1.4	2
170	Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 2831-2831.	1.4	11
171	Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis. <i>Blood</i> , 2016, 128, 3221-3221.	1.4	3
172	The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3232-3232.	1.4	16
173	Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism. <i>Blood</i> , 2016, 128, 3238-3238.	1.4	5
174	The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3941-3941.	1.4	3
175	Natural History of Non-Infectious, Ibrutinib-Attributable Adverse Events Leading to Alternative BTK Inhibitor Use in CLL. <i>Blood</i> , 2016, 128, 4385-4385.	1.4	2
176	Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones. <i>Blood</i> , 2016, 128, 4386-4386.	1.4	2
177	Factors That Influence Patient Treatment Decision Making in the Era of Novel Agents: An Internet-Based Survey of 281 Patients with CLL. <i>Blood</i> , 2016, 128, 4398-4398.	1.4	1
178	Toxicities and Related Outcomes of Elderly Patients (pts) (≥ 65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). <i>Blood</i> , 2016, 128, 536-536.	1.4	1
179	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	1.4	8
180	SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model. <i>Blood</i> , 2016, 128, 580-580.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639.	1.4	22
182	Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 28684-28696.	1.8	9
183	Suppression of Anti-Tumor Immunity in Chronic Lymphocytic Leukemia Via Interleukin-10 Production. <i>Blood</i> , 2016, 128, 3215-3215.	1.4	0
184	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. <i>Blood</i> , 2016, 128, 3198-3198.	1.4	0
185	The Mutational Patterns Associated with Cytogenetic Subsets of De Novo Acute Myeloid Leukemia (AML): A Study of 1603 Adult Patients (Pts). <i>Blood</i> , 2016, 128, 287-287.	1.4	0
186	Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo. <i>Blood</i> , 2016, 128, 352-352.	1.4	1
187	CCND1 and CCND2 Mutations Are Frequent in Adults with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) with t(8;21)(q22;q22). <i>Blood</i> , 2016, 128, 2740-2740.	1.4	0
188	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	1.4	0
189	Exploring the Role of the Recurrent Exportin 1 (XPO1/CRM1) Mutations E571G and E571K in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 972-972.	1.4	1
190	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. <i>Blood</i> , 2016, 128, 2767-2767.	1.4	0
191	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015, 125, 284-295.	1.4	19
192	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. <i>Blood</i> , 2015, 125, 3297-3305.	1.4	138
193	Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective. <i>Haematologica</i> , 2015, 100, e18-e20.	3.5	7
194	Proteomic profiling identifies specific histone species associated with leukemic and cancer cells. <i>Clinical Proteomics</i> , 2015, 12, 22.	2.1	18
195	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	2.5	8
196	Role of B cell receptor signaling in IL-10 production by normal and malignant B cells. <i>Annals of the New York Academy of Sciences</i> , 2015, 1362, 239-249.	3.8	28
197	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 1884-1888.	1.8	49
198	Tetraspanins as therapeutic targets in hematological malignancy: a concise review. <i>Frontiers in Physiology</i> , 2015, 6, 91.	2.8	44

#	ARTICLE	IF	CITATIONS
199	Antagonizing ClpP: A New Power Play in Targeted Therapy for AML. <i>Cancer Cell</i> , 2015, 27, 747-749.	16.8	6
200	Epigenetic silencing of miR-708 enhances NF- κ B signaling in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2015, 137, 1352-1361.	5.1	52
201	ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. <i>Experimental Hematology</i> , 2015, 43, 770-774.e2.	0.4	16
202	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. <i>Leukemia Research</i> , 2015, 39, 1270-1277.	0.8	11
203	Magnetic Tweezers-Based 3D Microchannel Electroporation for High-Throughput Gene Transfection in Living Cells. <i>Small</i> , 2015, 11, 1818-1828.	10.0	83
204	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2169-2174.	7.1	63
205	Granzyme B Expression Is Enhanced in Human Monocytes by TLR8 Agonists and Contributes to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Immunology</i> , 2015, 194, 2786-2795.	0.8	41
206	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80.	7.1	498
207	IGHV and Interphase Cytogenetics in a Patient With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 681.	7.1	0
208	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.4	19
209	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4322-4327.	7.1	38
210	Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 3128-3132.	1.4	84
211	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. <i>Journal of Immunology</i> , 2015, 195, 1995-2005.	0.8	25
212	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in SÅzary syndrome. <i>Nature Communications</i> , 2015, 6, 8470.	12.8	177
213	Histone Deacetylase Inhibitors Induce microRNAs Targeting BTK in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1222-1222.	1.4	1
214	Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1232-1232.	1.4	1
215	The Role of Tetraspanin CD37 in B-Cell Malignancy. <i>Blood</i> , 2015, 126, 1258-1258.	1.4	1
216	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1713-1713.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2436-2436.	1.4	1
218	ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity. Blood, 2015, 126, 2908-2908.	1.4	15
219	The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2911-2911.	1.4	2
220	The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2920-2920.	1.4	7
221	Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2940-2940.	1.4	3
222	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2951-2951.	1.4	10
223	A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 2953-2953.	1.4	2
224	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	1.4	23
225	Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget, 2015, 6, 2667-2679.	1.8	41
226	CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF- κ B mediated pathway. Oncotarget, 2015, 6, 15931-15939.	1.8	8
227	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 2015, 6, 31134-31150.	1.8	38
228	A Novel Inhibitor of BET Family Bromodomains Demonstrates In Vivo and In Vitro Potency in B-Cell Malignancies. Blood, 2015, 126, 318-318.	1.4	0
229	BRAFV600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation. Blood, 2015, 126, 2477-2477.	1.4	0
230	Effects of the Btk Inhibitor Ibrutinib on Monocyte Responses to Antibodies. Blood, 2015, 126, 1017-1017.	1.4	9
231	In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease. Blood, 2015, 126, 2471-2471.	1.4	0
232	Immunoliposomal Delivery of Mir-29b By Targeting Tumor Antigen ROR1 Induces Epigenetic Reprogramming in Human-ROR1-Expressed Mouse Model of Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1743-1743.	1.4	0
233	The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. Blood, 2015, 126, 831-831.	1.4	0
234	The E μ -Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. Blood, 2015, 126, 2752-2752.	1.4	8

#	ARTICLE	IF	CITATIONS
235	Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 88-88.	1.4	0
236	Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. <i>MAbs</i> , 2014, 6, 748-754.	5.2	37
237	A novel liposomal formulation of FTY720 (Fingolimod) for promising enhanced targeted delivery. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 393-400.	3.3	34
238	The B-Cell Receptor Pathway: A Critical Component of Healthy and Malignant Immune Biology. <i>Seminars in Hematology</i> , 2014, 51, 206-218.	3.4	25
239	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	10.7	438
240	PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data. <i>Bioinformatics</i> , 2014, 30, 3567-3574.	4.1	11
241	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	27.0	1,427
242	NF- κ B Functions in Tumor Initiation by Suppressing the Surveillance of Both Innate and Adaptive Immune Cells. <i>Cell Reports</i> , 2014, 9, 90-103.	6.4	60
243	A phase 1 study of the PI3K γ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014, 123, 3398-3405.	1.4	245
244	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	1.4	179
245	Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 98, 160-165.	2.8	4
246	A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1025-1029.	0.8	11
247	Chronic Lymphocytic Leukemia: State of the Art and Beyond. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 801-803.	4.9	0
248	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. <i>Blood</i> , 2014, 124, 3553-3560.	1.4	56
249	A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1302-1308.	1.4	62
250	Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2014, 123, 1207-1213.	1.4	176
251	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , 2014, 123, 1810-1817.	1.4	246
252	IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. <i>Blood</i> , 2014, 124, 3583-3586.	1.4	91

#	ARTICLE	IF	CITATIONS
253	Targeting Interleukin-2 Inducible T-Cell Kinase (ITK) in T-Cell Related Diseases. Postdoc Journal, 2014, 2, 1-11.	0.4	15
254	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2013, 369, 32-42.	27.0	2,019
255	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 2860-2860.	1.4	5
256	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study. Blood, 2013, 122, 4163-4163.	1.4	9
257	B-1239, a Novel Anti-BAFF-R Afucosylated Human Antibody, Promotes Potent Natural Killer Cell-Mediated Antibody Dependent Cellular Cytotoxicity In Chronic Lymphocytic Leukemia Cells In- Vitro and Depletion Of Circulating Leukemic CLL B Cells In-Vivo. Blood, 2013, 122, 4185-4185.	1.4	2
258	Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 871-871.	1.4	11
259	PKC Inhibitor AEB071 Demonstrates Pre-Clinical Activity In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 4187-4187.	1.4	0
260	OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. Blood, 2013, 122, 2523-2523.	1.4	0
261	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Cancer Cell, 2012, 21, 694-708.	16.8	122
262	A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL). Blood, 2012, 120, 1643-1643.	1.4	11
263	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood, 2012, 120, 189-189.	1.4	28
264	Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2012, 120, 719-719.	1.4	5
265	Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 691-694.	3.8	8
266	Therapeutic Targeting of B-Cell Receptor Signaling Pathways. Blood, 2012, 120, SCI-27-SCI-27.	1.4	8
267	Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.. Blood, 2012, 120, 2619-2619.	1.4	0
268	TLR7/8 Agonists Overcome the Suppression of FcγR Activity in Monocytes From Chronic Lymphocytic Leukemia Patients. Blood, 2012, 120, 4595-4595.	1.4	0
269	Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies.. Blood, 2012, 120, 2473-2473.	1.4	0
270	Fatigue, Distress, and Quality of Life As Covariates for Early-Stage Chronic Lymphocytic Leukemia. Blood, 2012, 120, 2075-2075.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and) Tj ETQq1 1 0.784314 rgBT /Overlock 1.4 0 Blood, 2012, 120, 3616-3616.	1.4	0
272	Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL.. Blood, 2012, 120, 2452-2452.	1.4	1
273	A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood, 2012, 120, 1800-1800.	1.4	0
274	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood, 2012, 120, 3865-3865.	1.4	0
275	The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 1362-1362.	1.4	0
276	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. Journal of Clinical Oncology, 2011, 29, 1349-1355.	1.6	124
277	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. Blood, 2011, 118, 288-288.	1.4	3
278	Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia. Blood, 2011, 118, 3090-3090.	1.4	1
279	Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma. Blood, 2011, 118, 595-595.	1.4	2
280	The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. Blood, 2011, 118, 983-983.	1.4	20
281	Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse. Blood, 2011, 118, 2838-2838.	1.4	0
282	Phase 1 Study of TRU-016, An Anti-CD37 SMIP, Protein in Relapsed and/or Refractory NHL Patients. Blood, 2011, 118, 1636-1636.	1.4	2
283	FTY720 Increases CD74 Expression and Sensitizes Mantle Cell Lymphoma Cells to Milatuzumab-Mediated Cell Death. Blood, 2011, 118, 600-600.	1.4	0
284	Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties,. Blood, 2011, 118, 3717-3717.	1.4	1
285	CRM1/XPO1 Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia. Blood, 2011, 118, 232-232.	1.4	1
286	Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,. Blood, 2011, 118, 3702-3702.	1.4	0
287	Juxtaposing CD20 and CD74 with Novel Bispecific Antibodies Evokes Potent Cytotoxicity in Mantle Cell Lymphoma (MCL). Blood, 2011, 118, 599-599.	1.4	0
288	A Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,. Blood, 2011, 118, 3912-3912.	1.4	2

#	ARTICLE	IF	CITATIONS
289	Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. Blood, 2011, 118, 1791-1791.	1.4	0
290	Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial.. Blood, 2011, 118, 3910-3910.	1.4	0
291	Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Blood, 2011, 118, 622-622.	1.4	0
292	Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells. Blood, 2011, 118, 929-929.	1.4	0
293	Phase 1 Study of Tru-016, An Anti-CD37 SMIP [®] , [®] Protein in Naïve and Relapsed and/or Refractory CLL Patients. Blood, 2011, 118, 1792-1792.	1.4	2
294	Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma.. Blood, 2011, 118, 3707-3707.	1.4	0
295	Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101. Journal of Clinical Oncology, 2010, 28, 4500-4506.	1.6	71
296	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. Blood, 2010, 116, 2456-2456.	1.4	1
297	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. Blood, 2010, 116, 1378-1378.	1.4	0
298	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 1232-1234.	1.3	0
299	Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 2070-2070.	1.4	1
300	A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIPTM) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity.. Blood, 2009, 114, 3424-3424.	1.4	9
301	Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).. Blood, 2009, 114, 838-838.	1.4	50
302	Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110 ^δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.. Blood, 2009, 114, 922-922.	1.4	24
303	Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 1374-1374.	1.4	23
304	Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study.. Blood, 2009, 114, 1614-1614.	1.4	0
305	OSU-DY7, a Novel D-Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway.. Blood, 2009, 114, 3778-3778.	1.4	0
306	Evidence of MicroRNA-29b and Sp1/NF ^κ B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. Blood, 2009, 114, 938-938.	1.4	1

#	ARTICLE	IF	CITATIONS
307	CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.. Blood, 2009, 114, 3725-3725.	1.4	0
308	Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression.. Blood, 2009, 114, 1737-1737.	1.4	0
309	Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCeâ,,¢ SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells.. Blood, 2009, 114, 1744-1744.	1.4	0
310	Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.. Blood, 2008, 112, 1571-1571.	1.4	1
311	A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkinâ€™s Lymphoma. Blood, 2008, 112, 3053-3053.	1.4	1
312	CAL-101, a Selective Inhibitor of the p110Î´ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease. Blood, 2008, 112, 3165-3165.	1.4	4
313	Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 3300-3300.	1.4	0
314	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkinâ€™s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. Blood, 2008, 112, 3169-3169.	1.4	0
315	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).. Blood, 2008, 112, 2170-2170.	1.4	0
316	NF-ÎºB Is Active in Mcl-1 Promoter Regulation in Human CLL.. Blood, 2008, 112, 2265-2265.	1.4	1
317	Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood, 2007, 109, 399-404.	1.4	367
318	Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research, 2007, 31, 1737-1740.	0.8	14
319	del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement.. Blood, 2007, 110, 2073-2073.	1.4	1
320	Recombinant Interleukin-21 Plus Rituximab: Clinical Activity in a Phase 1, Dose-Finding Trial in Relapsed Low-Grade B Cell Lymphoma.. Blood, 2007, 110, 2577-2577.	1.4	6
321	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. Blood, 2007, 110, 3104-3104.	1.4	3
322	The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL.. Blood, 2007, 110, 3123-3123.	1.4	1
323	Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901).. Blood, 2007, 110, 756-756.	1.4	9
324	Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses.. Blood, 2007, 110, 4727-4727.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.. Blood, 2007, 110, 3128-3128.	1.4	5
326	Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy. Journal of Clinical Oncology, 2006, 24, 437-443.	1.6	233
327	Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood, 2006, 108, 1334-1338.	1.4	112
328	Treatment of Relapsed Chronic Lymphocytic Leukemia: Old and New Therapies. Seminars in Oncology, 2006, 33, 210-219.	2.2	26
329	NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL.. Blood, 2006, 108, 135-135.	1.4	3
330	Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells.. Blood, 2006, 108, 2600-2600.	1.4	2
331	Pharmacokinetics and Pharmacodynamics from a First-in-Human Phase 1 Dose Escalation Study with Antagonist Anti-CD40 Antibody, HCD122 (Formerly CHIR-12.12), in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2837-2837.	1.4	10
332	A Phase II Study of the TNF-Î± Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.. Blood, 2006, 108, 2841-2841.	1.4	4
333	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood, 2006, 108, 2845-2845.	1.4	4
334	Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.. Blood, 2006, 108, 302-302.	1.4	6
335	CD37â€™SMIPTM Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. Blood, 2006, 108, 753-753.	1.4	3
336	Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkinâ€™s Lymphoma.. Blood, 2006, 108, 2768-2768.	1.4	0
337	The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .. Blood, 2006, 108, 2833-2833.	1.4	0
338	Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality.. Blood, 2006, 108, 5515-5515.	1.4	3
339	Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2006, 108, 2098-2098.	1.4	0
340	Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2792-2792.	1.4	0
341	The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia.. Blood, 2006, 108, 2807-2807.	1.4	1
342	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood, 2005, 105, 49-53.	1.4	376

#	ARTICLE	IF	CITATIONS
343	Treatment of Relapsed Chronic Lymphocytic Leukemia by 72-Hour Continuous Infusion or 1-Hour Bolus Infusion of Flavopiridol: Results from Cancer and Leukemia Group B Study 19805. Clinical Cancer Research, 2005, 11, 4176-4181.	7.0	124
344	Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma.. Blood, 2005, 106, 2407-2407.	1.4	5
345	Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.. Blood, 2005, 106, 944-944.	1.4	5
346	Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.. Blood, 2005, 106, 2124-2124.	1.4	1
347	Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. Journal of Clinical Oncology, 2004, 22, 1087-1094.	1.6	190
348	A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2004, 105, 959-967.	1.4	371
349	Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 339-339.	1.4	18
350	Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 341-341.	1.4	17
351	Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 3486-3486.	1.4	3
352	Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997.. Blood, 2004, 104, 3487-3487.	1.4	8
353	Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Based Treatment Used.. Blood, 2004, 104, 949-949.	1.4	2
354	Motexafin Gadolinium Induces Apoptosis in Lymphoid Cell Lines and Demonstrates Enhanced Biological Activity with Akt Kinase Inhibitors.. Blood, 2004, 104, 3406-3406.	1.4	1
355	Sequential Phase II Studies of Flavopiridol by 72-Hour Continuous Infusion and 1-Hour Intravenous Bolus for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia: Results from CALGB Study 19805.. Blood, 2004, 104, 3485-3485.	1.4	0
356	Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.. Blood, 2004, 104, 2492-2492.	1.4	9
357	Leflunomide Inhibits Proliferation of Neoplastic B-Cell Lines and Induces Apoptosis in Primary CLL Cells.. Blood, 2004, 104, 2497-2497.	1.4	0
358	Generation and Analysis of Transgenic Mice Reveal a Role for CRE Binding Proteins in Multiple Stages of B Cell Development, Functional Maturation, Proliferation and Apoptosis.. Blood, 2004, 104, 3233-3233.	1.4	3
359	Single Institution Experience with Two High-Dose Chemotherapy (HDC) Conditioning Regimens Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM).. Blood, 2004, 104, 5214-5214.	1.4	0
360	Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy.. Blood, 2004, 104, 476-476.	1.4	3

#	ARTICLE	IF	CITATIONS
361	A Phase II Study of the TNF-Î± Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities.. Blood, 2004, 104, 3469-3469.	1.4	1
362	Alemtuzumab Induces Cell Death in Human Chronic Lymphocytic Leukemia Cells through a Lipid Raft-Dependent Mechanism.. Blood, 2004, 104, 2507-2507.	1.4	0
363	The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2.. Blood, 2004, 104, 2802-2802.	1.4	0
364	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 2003, 101, 6-14.	1.4	549
365	Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Research, 2003, 63, 36-8.	0.9	68
366	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002, 100, 4325-4336.	1.4	1,444
367	The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 2002, 99, 1038-1043.	1.4	350
368	Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer, 2002, 94, 2033-2039.	4.1	115
369	Frequency and type of serious infections in fludarabineâ€refractory Bâ€cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer, 2002, 94, 2033-2039.	4.1	6
370	Novel Presentation of Acute Myelogenous Leukemia as Symptomatic Galactorrhea. Annals of Internal Medicine, 2001, 135, 303.	3.9	10
371	Carboxyamido-Triazole (CAI)-a Novel â€œstaticâ€Signal Transduction Inhibitor Induces Apoptosis in Human B-Cell Chronic Lymphocytic Leukemia Cells. Leukemia and Lymphoma, 2001, 42, 1049-1053.	1.3	8
372	Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565. Journal of Clinical Oncology, 2000, 18, 2780-2787.	1.6	177
373	Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered. Journal of Clinical Oncology, 1999, 17, 3767-3775.	1.6	290